Sexually Transmitted Diseases (STD) Testing Market Size, Trends, Growth & Outlook

Sexually Transmitted Diseases (STD) Testing Market by Disease Type (Chlamydia, Syphilis, Gonorrhea, Herpes Simplex Virus, Human Papilloma Virus, Human Immunodeficiency Virus, and Others), and Location of Testing (Laboratory Testing and POC Testing): Global Opportunity Analysis and Industry Forecast, 2018–2025

Industry: Life Science | Report ID: FAMI-00153 | Published on: Aug, 2019 | View: 247 | Share:         

Request Sample Enquire Before Buying Request Discount

  • Report Descripton
  • Table Of Content
  • Request Methodology
  • Request Customization

According to a new report published by Allied Market Research, titled, ""Sexually Transmitted Diseases (STD) Testing Market by Disease Type and Location of Testing: Global Opportunity Analysis and Industry Forecast, 2018-2025,"" the global STD testing market is expected to reach $133,935.7 million by 2025, registering a CAGR of 5.6% from 2018 to 2025.

At present, sexually transmitted diseases are considered as one of the most critical health challenges globally. Chlamydia, gonorrhea, and herpes simplex virus are some of the highly prevalent sexually transmitted diseases.The STD testing market has gained prominence in the recent years due to high prevalence of major sexually transmitted diseases worldwide and as a result, increase in need for STD diagnosis. However, limited access to STD diagnosis in majority of the population from developing regions is expected to restrain the market growth.

Based on disease type, the chlamydia segment is the highest revenue contributor and gonorrhea is expected to exhibit the fastest growth rate of 8.9%. This is attributed to the increased prevalence of gonorrhea in the last decade.

Asia-Pacific was the highest revenue contributor in the global STD testing market, accounting for 54.0% share in 2017. This region is also expected to grow at the highest rate, owing to the number of developing nations present in this region, rise in prevalence of sexually transmitted diseases, and increase in awareness.

Based on location of testing, the laboratory testing segment occupied the largest share of STD testing market in 2017. POC testing segment is expected to grow at the highest rate during the forecast period. Factors such as faster diagnosis with POC tests and expected rise in adoption of POCs in future, significantly contribute toward the growth of this segment.

Key Findings Of The Study

LAMEA occupied 40.0% share of the global STD testing market in 2017.
The Asia-Pacific segment is anticipated to grow with the highest CAGR throughout the forecast period.
The laboratory testing segment accounted for 85.0% share of the market in 2017.
The POC testing segment is anticipated to grow at the highest rate during the analysis period.

The major companies profiled in this report include Roche Holdings AG, BioMerieux, Hologic Inc., Becton Dickinson & Company, Cepheid Inc., Danaher Corporation, Affymetrix, Alere Inc., Abbott Laboratories, Bio-Rad Laboratories Inc., and DiaSorin.

Get a sample pages of this report Click here

CHAPTER 1:INTRODUCTION

1.1.REPORT DESCRIPTION
1.2.KEY MARKET SEGMENTS
1.3.KEY BENEFITS
1.4.RESEARCH METHODOLOGY

1.4.1.Primary research
1.4.2.Secondary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.CXO PERSPECTIVE

CHAPTER 3:MARKET OVERVIEW

3.1.MARKET DEFINITION AND SCOPE
3.2.KEY FINDINGS

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.MARKET DYNAMICS

3.3.1. Drivers
3.3.2. Restraints
3.3.3. Opportunities

CHAPTER 4:STD TESTING MARKET BY DISEASE TYPE

4.1.OVERVIEW
4.2. CHLAMYDIA

4.2.1.Key market trends, Growth factors and opportunities
4.2.2.Market size and forecast by region
4.2.3.Market volume and forecast by region

4.3. GONORRHEA

4.3.1.Key market trends, Growth factors and opportunities
4.3.2.Market size and forecast by region
4.3.3.Market volume and forecast by region

4.4. HERPES SIMPLEX VIRUS

4.4.1.Key market trends, Growth factors and opportunities
4.4.2.Market size and forecast by region
4.4.3.Market volume and forecast by region

4.5. SYPHILIS

4.5.1.Key market trends, Growth factors and opportunities
4.5.2.Market size and forecast by region
4.5.3.Market volume and forecast by region

4.6. HUMAN PAPILLOMA VIRUS

4.6.1.Key market trends, Growth factors and opportunities
4.6.2.Market size and forecast by region
4.6.3.Market volume and forecast by region

4.7. HUMAN IMMUNODEFICIENCY VIRUS

4.7.1.Key market trends, Growth factors and opportunities
4.7.2.Market size and forecast by region
4.7.3.Market volume and forecast by region

4.8. OTHERS

4.8.1.Key market trends, Growth factors and opportunities
4.8.2.Market size and forecast by region
4.8.3.Market volume and forecast by region

CHAPTER 5:STD TESTING MARKET BY LOCATION OF TESTING

5.1.OVERVIEW
5.2. LABORATORY TESTING

5.2.1.Key market trends, Growth factors and opportunities
5.2.2.Market size and forecast by region
5.2.3.Market volume and forecast by region

5.3. POINT OF CARE TESTING

5.3.1.Key market trends, Growth factors and opportunities
5.3.2.Market size and forecast by region
5.3.3.Market volume and forecast by region

CHAPTER 6:STD TESTING MARKET BY REGION

6.1.OVERVIEW
6.2.NORTH AMERICA

6.2.1.Key market trends and opportunities
6.2.2.Market size and forecast by Disease Type
6.2.3.Market size and forecast by Location of Testing

6.3.EUROPE

6.3.1.Key market trends and opportunities
6.3.2.Market size and forecast by Disease Type
6.3.3.Market size and forecast by Location of Testing

6.4.ASIA PACIFIC

6.4.1.Key market trends and opportunities
6.4.2.Market size and forecast by Disease Type
6.4.3.Market size and forecast by Location of Testing

6.5.LAMEA

6.5.1.Key market trends and opportunities
6.5.2.Market size and forecast by Disease Type
6.5.3.Market size and forecast by Location of Testing

CHAPTER 7:COMPANY PROFILES

7.1. ROCHE HOLDINGS AG

7.1.1.Company overview
7.1.2.Business performance
7.1.3.Key strategic moves and developments

7.2. BIOMERIEUX

7.2.1.Company overview
7.2.2.Business performance
7.2.3.Key strategic moves and developments

7.3. HOLOGIC INC

7.3.1.Company overview
7.3.2.Business performance
7.3.3.Key strategic moves and developments

7.4. BECTON DICKINSON COMPANY

7.4.1.Company overview
7.4.2.Business performance
7.4.3.Key strategic moves and developments

7.5. ORASURE

7.5.1.Company overview
7.5.2.Business performance
7.5.3.Key strategic moves and developments

7.6. DANAHER CORPORATION

7.6.1.Company overview
7.6.2.Business performance
7.6.3.Key strategic moves and developments

7.7. AFFYMETRIX

7.7.1.Company overview
7.7.2.Business performance
7.7.3.Key strategic moves and developments

7.8. ABBOTT LABORATORIES

7.8.1.Company overview
7.8.2.Business performance
7.8.3.Key strategic moves and developments

7.9. BIO-RAD LABORATORIES INC

7.9.1.Company overview
7.9.2.Business performance
7.9.3.Key strategic moves and developments

7.10. DIASORIN

7.10.1.Company overview
7.10.2.Business performance
7.10.3.Key strategic moves and developments

LIST OF TABLES

TABLE 1.GLOBAL STD TESTING MARKET, BY DISEASE TYPE 2017-2025 ($MILLION)
TABLE 2.STD TESTING MARKET FOR CHLAMYDIA, BY REGION, 2017-2025 ($MILLION)
TABLE 3.STD TESTING MARKET FOR GONORRHEA, BY REGION, 2017-2025 ($MILLION)
TABLE 4.STD TESTING MARKET FOR HERPES SIMPLEX VIRUS, BY REGION, 2017-2025 ($MILLION)
TABLE 5.STD TESTING MARKET FOR SYPHILIS, BY REGION, 2017-2025 ($MILLION)
TABLE 6.STD TESTING MARKET FOR HUMAN PAPILLOMA VIRUS, BY REGION, 2017-2025 ($MILLION)
TABLE 7.STD TESTING MARKET FOR HUMAN IMMUNODEFICIENCY VIRUS, BY REGION, 2017-2025 ($MILLION)
TABLE 8.STD TESTING MARKET FOR OTHERS, BY REGION, 2017-2025 ($MILLION)
TABLE 9.GLOBAL STD TESTING MARKET, BY LOCATION OF TESTING 2017-2025 ($MILLION)
TABLE 10.STD TESTING MARKET FOR LABORATORY TESTING, BY REGION, 2017-2025 ($MILLION)
TABLE 11.STD TESTING MARKET FOR POINT OF CARE TESTING, BY REGION, 2017-2025 ($MILLION)
TABLE 12.STD TESTING MARKET FOR, BY REGION, 2017-2025 ($MILLION)
TABLE 13.NORTH AMERICA STD TESTING, BY DISEASE TYPE 2017-2025 ($MILLION)
TABLE 14.NORTH AMERICA STD TESTING, BY LOCATION OF TESTING 2017-2025 ($MILLION)
TABLE 15.NORTH AMERICA STD TESTING, BY REGION, 2017-2025 ($MILLION)
TABLE 16.EUROPE STD TESTING, BY DISEASE TYPE 2017-2025 ($MILLION)
TABLE 17.EUROPE STD TESTING, BY LOCATION OF TESTING 2017-2025 ($MILLION)
TABLE 18.EUROPE STD TESTING, BY REGION, 2017-2025 ($MILLION)
TABLE 19.ASIA PACIFIC STD TESTING, BY DISEASE TYPE 2017-2025 ($MILLION)
TABLE 20.ASIA PACIFIC STD TESTING, BY LOCATION OF TESTING 2017-2025 ($MILLION)
TABLE 21.ASIA PACIFIC STD TESTING, BY REGION, 2017-2025 ($MILLION)
TABLE 22.LAMEA STD TESTING, BY DISEASE TYPE 2017-2025 ($MILLION)
TABLE 23.LAMEA STD TESTING, BY LOCATION OF TESTING 2017-2025 ($MILLION)
TABLE 24.LAMEA STD TESTING, BY REGION, 2017-2025 ($MILLION)
TABLE 25.ROCHE HOLDINGS AG: COMPANY SNAPSHOT
TABLE 26.ROCHE HOLDINGS AG: OPERATING SEGMENTS
TABLE 27.BIOMERIEUX: COMPANY SNAPSHOT
TABLE 28.BIOMERIEUX: OPERATING SEGMENTS
TABLE 29.HOLOGIC INC: COMPANY SNAPSHOT
TABLE 30.HOLOGIC INC: OPERATING SEGMENTS
TABLE 31.BECTON DICKINSON COMPANY: COMPANY SNAPSHOT
TABLE 32.BECTON DICKINSON COMPANY: OPERATING SEGMENTS
TABLE 33.ORASURE: COMPANY SNAPSHOT
TABLE 34.ORASURE: OPERATING SEGMENTS
TABLE 35.DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 36.DANAHER CORPORATION: OPERATING SEGMENTS
TABLE 37.AFFYMETRIX: COMPANY SNAPSHOT
TABLE 38.AFFYMETRIX: OPERATING SEGMENTS
TABLE 39.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 40.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 41.BIO-RAD LABORATORIES INC: COMPANY SNAPSHOT
TABLE 42.BIO-RAD LABORATORIES INC: OPERATING SEGMENTS
TABLE 43.DIASORIN: COMPANY SNAPSHOT
TABLE 44.DIASORIN: OPERATING SEGMENTS

Select License Type
  • Single User License $5370 USD
  • Multi-User License $6450 USD
  • Corporate User License $8995 USD

Our Clients

  • +1 518-300-1215Mon-Fri, 24Hrs
  • [email protected]We reply within an hours
  • Albany,
    NY, USA.